Acute liver allograft antibody-mediated rejection: An inter-institutional study of significant histopathological features

Liver Transplantation

Volumn 20, Issue 10, 2014, Pages 1244-1255

  O'Leary, Jacqueline G ^a   Shiller, S Michelle ^a   Bellamy, Christopher ^b   Nalesnik, Michael A ^c   Kaneku, Hugo ^d,e   Jennings, Linda W ^a   Isse, Kumiko ^c   Terasaki, Paul I ^e   Klintmalm, Göran B ^a   Demetris, Anthony J ^c  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e TERASAKI FOUNDATION LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C4D; LIPOFUSCIN; ALLOANTIBODY; HLA ANTIGEN;

ADULT; ANTIBODY MEDIATED REJECTION; ARTICLE; CHOLESTASIS; CONTROLLED STUDY; CYTOTOXICITY; DISEASE SEVERITY; ENDOTHELIUM CELL; EOSINOPHILIA; FEMALE; HEPATITIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL; LIVER GRAFT REJECTION; LIVER HISTOLOGY; LIVER HYPERTROPHY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; VALIDATION STUDY; ACUTE DISEASE; ADVERSE EFFECTS; ALLOGRAFT; BIOPSY; FOLLOW UP; GRAFT REJECTION; IMMUNOLOGY; LIVER; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; TIME;

ACUTE DISEASE; ADULT; ALLOGRAFTS; BIOPSY; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HLA ANTIGENS; HUMANS; ISOANTIBODIES; LIVER; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84908545973     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23948     Document Type: Article

References (46)

1. Demetris AJ, Jaffe R, Tzakis A, Ramsey G, Todo S, Belle S, et al. Antibody-mediated rejection of human orthotopic liver allografts. A study of liver transplantation across ABO blood group barriers. Am J Pathol 1988;132:489-502.
2. Gordon RD, Iwatsuki S, Esquivel CO, Tzakis A, Todo S, Starzl TE. Liver transplantation across ABO blood groups. Surgery 1986;100:342-348.
3. Starzl TE, Marchioro TL, Holmes JH, Hermann G, Brittain RS, Stonington OH, et al. Renal homografts in patients with major donor-recipient blood group incompatibilities. Surgery 1964;55:195-200.
4. Terasaki P, Marchioro T, Starzl T. Histocompatibility Testing. Washington, DC: National Academy of Sciences; 1965.
5. Kissmeyer-Nielsen F, Olsen S, Petersen VP, Fjeldborg O. Hyperacute rejection of kidney allografts, associated with pre-existing humoral antibodies against donor cells. Lancet 1966;2:662-665.
6. Andres GA, Ansell ID, Halgrimson CG, Hsu KC, Porter KA, Starzl TE, et al. Immunopathological studies of orthotopic human liver allografts. Lancet 1972;1:275-280.
7. Demetris AJ, Nakamura K, Yagihashi A, Iwaki Y, Takaya S, Hartman GG, et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 1992;16:671-681.
8. Demetris AJ, Murase N, Nakamura K, Iwaki Y, Yagihashi A, Valdivia L, et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin Liver Dis 1992;12:51-59.
9. Nakamura K, Murase N, Becich MJ, Furuya T, Todo S, Fung JJ, et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am J Pathol 1993;142:1383-1391.
10. Takaya S, Duquesnoy R, Iwaki Y, Demetris J, Yagihashi A, Bronsther O, et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant Proc 1991;23(pt 1):396-399.
11. Mañez R, Kelly RH, Kobayashi M, Takaya S, Bronsther O, Kramer D, et al. Immunoglobulin G lymphocytotoxic antibodies in clinical liver transplantation: studies toward further defining their significance. Hepatology 1995;21:1345-1352.
12. Donaldson PT, Alexander GJ, O'Grady J, Neuberger J, Portmann B, Thick M, et al. Evidence for an immune response to HLA class I antigens in the vanishingbileduct syndrome after liver transplantation. Lancet 1987;1:945-951.
13. Batts KP, Moore SB, Perkins JD, Wiesner RH, Grambsch PM, Krom RA. Influence of positive lymphocyte crossmatch and HLA mismatching on vanishing bile duct syndrome in human liver allografts. Transplantation 1988;45:376-379.
14. Knechtle SJ, Kolbeck P, Tsuchimoto S, Sanfilippo F, Bollinger RR. Hyperacute rejection of liver transplants in rats. Curr Surg 1986;43:303-305.
15. Knechtle SJ, Kolbeck PC, Tsuchimoto S, Coundouriotis A, Sanfilippo F, Bollinger RR. Humoral rejection of rat hepatic transplants by passive transfer of serum. Transplant Proc 1987;19(pt 2):1072-1076.
16. TaitBD, Süsal C,GebelHM, Nickerson PW, Zachary AA, Claas FH, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013;95:19-47.
17. O'Leary JG, Kaneku H, Jennings LW, Bañuelos N, Susskind BM, Terasaki PI, Klintmalm GB. Preformed class II donor-specific antibodies are associated with an increased risk of early rejection after liver transplantation. Liver Transpl 2013;19:973-980.
18. Taner T, Gandhi MJ, Sanderson SO, Poterucha CR, De Goey SR, Stegall MD, Heimbach JK. Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am J Transplant 2012; 12:1504-1510.
19. O'Leary JG, Demetris AJ, Friedman LS, Gebel HM, Halloran PF, Kirk AD, et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am J Transplant 2014;14:779-787.
20. O'Leary JG, Kaneku H, Susskind BM, Jennings LW, Neri MA, Davis GL, et al. High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am J Transplant 2011;11:1868-1876.
21. O'Leary JG, Klintmalm GB. Impact of donor-specific antibodies on results of liver transplantation. Curr Opin Organ Transplant 2013;18:279-284.
22. Musat AI, Agni RM, Wai PY, Pirsch JD, Lorentzen DF, Powell A, et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am J Transplant 2011;11:500-510.
23. Kozlowski T, Rubinas T, Nickeleit V, Woosley J, Schmitz J, Collins D, et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transpl 2011;17:357-368.
24. O'Leary JG, Kaneku H, Demetris AJ, Marr JD, Shiller SM, Susskind BM, et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transpl 2014;20:218-227.
25. Kaneku H, O'Leary JG, Taniguchi M, Susskind BM, Terasaki PI, Klintmalm GB. Donor-specific human leukocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transpl 2012;18:984-992.
26. Kozlowski T, Andreoni K, Schmitz J, Hayashi PH, Nickeleit V. Sinusoidal C4d deposits in liver allografts indicate an antibody-mediated response: diagnostic considerations in the evaluation of liver allografts. Liver Transpl 2012;18:641-658.
27. Lunz J, Ruppert KM, Cajaiba MM, Isse K, Bentlejewski CA, Minervini M, et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant 2012;12:171-182.
28. Bellamy CO. Complement C4d immunohistochemistry in the assessment of liver allograft biopsy samples: applications and pitfalls. Liver Transpl 2011;17:747-750.
29. Hübscher SG. Antibody-mediated rejection in the liver allograft. Curr Opin Organ Transplant 2012;17:280-286.
30. Paterno F, Shiller M, Tillery G, O'Leary JG, Susskind B, Trotter J, Klintmalm GB. Bortezomib for acute antibodymediated rejection in liver transplantation. Am J Transplant 2012;12:2526-2531.
31. Starzl TE, Demetris AJ, Todo S, Kang Y, Tzakis A, Duquesnoy R, et al. Evidence for hyperacute rejection of human liver grafts: the case of the canary kidneys. Clin Transplant 1989;3:37-45.
32. Martin T, Schwartz J, Demetris A, Comstock J, Lowichik A, Book L. Plasmapheresis treatment of antibodymediated rejection in an A2 donor to O pediatric liver transplant recipient. Pediatr Transplant 2011;15:E15-E18.
33. Hallgren KA. Computing inter-rater reliability for observational data: an overview and tutorial. Tutor Quant Methods Psychol 2012;8:23-34.
34. Weil R III, Clarke DR, Iwaki Y, Porter KA, Koep LJ, Paton BC, et al. Hyperacute rejection of a transplanted human heart. Transplantation 1981;32:71-72.
35. Jaramillo A, Smith MA, Phelan D, Sundaresan S, Trulock EP, Lynch JP, et al. Development of ELISAdetected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999;67:1155-1161.
36. de Kort H, Roufosse C, Bajema IM, Drachenberg CB. Pancreas transplantation, antibodies and rejection: where do we stand? Curr Opin Organ Transplant 2013; 18:337-344.
37. Berry G, Burke M, Andersen C, Angelini A, Bruneval P, Calabrese F, et al. Pathology of pulmonary antibodymediated rejection: 2012 update from the Pathology Council of the ISHLT. J Heart Lung Transplant 2013;32: 14-21.
38. Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al.; for Banff Meeting Report Writing Committee. Banff 2013 meeting report: inclusion of C4d-negative antibodymediated rejection and antibody-associated arterial lesions. Am J Transplant 2014;14:272-283.
39. Berry GJ, Burke MM, Andersen C, Bruneval P, Fedrigo M, Fishbein MC, et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant 2013;32:1147-1162.
40. Solez K, Racusen LC. The Banff classification revisited. Kidney Int 2013;83:201-206.
41. Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, et al.; for Banff Meeting Report Writing Committee. Banff 2011 meeting report: new concepts in antibody-mediated rejection. Am J Transplant 2012;12: 563-570.
42. Feng S, Ekong UD, Lobritto SJ, Demetris AJ, Roberts JP, Rosenthal P, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012;307:283-293.
43. Takaya S, Bronsther O, Iwaki Y, Nakamura K, Abu-Elmagd K, Yagihashi A, et al. The adverse impact on liver transplantation of using positive cytotoxic crossmatch donors. Transplantation 1992;53:400-406.
44. Kaneku H, O'Leary JG, Banuelos N, Jennings LW, Susskind BM, Klintmalm GB, Terasaki PI. De novo donor-specific HLA antibodies decrease patient and graft survival in liver transplant recipients. Am J Transplant 2013;13:1541-1548.
45. Salah A, Fujimoto M, Yoshizawa A, Yurugi K, Miyagawa-Hayashino A, Sumiyoshi S, et al. Application of complement component 4d immunohistochemistry to ABOcompatible and ABO-incompatible liver transplantation. Liver Transpl 2014;20:200-209.
46. Datta Gupta S, Hudson M, Burroughs AK, Morris R, Rolles K, Amlot P, et al. Grading of cellular rejection after orthotopic liver transplantation. Hepatology 1995;21: 46-57.